Navigation Links
Major EPSRC Programme Grant to support new Oxford Centre for Drug Delivery Devices

Cancer therapy drugs tend to achieve limited accumulation and poor penetration in tumours, reducing their effectiveness. For many years, the only methods used to improve drug uptake by tumours have been pharmacological, and these have had limited success.

Recent research at Oxford University has shown that physical mechanisms triggered by ultrasound, magnetic fields or shock waves can dramatically improve the delivery and penetration of existing and experimental drugs into tumours.

Now a new research centre, The Oxford Centre for Drug Delivery Devices (OxCD3), will look to exploit engineering approaches, involving a combination of stimulus- responsive nanocarriers and medical devices already in clinical use, to improve the therapeutic outcomes of drug-based cancer treatments.

The new centre will be based at the University of Oxford and has been made possible by a 10.1 million Programme Grant which includes 6.4 million from the Engineering and Physical Sciences Research Council (EPSRC).

Led by Professors Coussios, Stride, Carlisle and Cleveland in the Institute of Biomedical Engineering, OxCD3 represents a partnership between the Department of Engineering Science, the Department of Oncology (Professors Seymour, Sibson and Vallis), the MRC Weatherall Institute of Molecular Medicine (Prof. Rabbitts), the Nuffield Department of Surgical Science (Prof. Friend) and the Clinical Biomanufacturing Facility (Dr Moyle).

The principal investigator, Professor Constantin Coussios, said: "We are very grateful to EPSRC, our industrial partners and the University of Oxford for their support of OxCD3. This will enable the creation of a sustainable, world-‐ unique multi-‐disciplinary environment for combinational engineering of biology, chemistry and medical devices to improve drug delivery under a single roof. It is also expected to create a much-‐needed training environment for the next generation of young scientists working on combination therapies and biomedical nanotechnology, by providing direct exposure to regulatory and manufacturing issues encountered when translating laboratory research into production and clinical practice."

The new Centre will initially focus on improving the delivery of several classes of cancer drugs, ranging from conventional chemotherapy and radiopharmaceuticals to next-‐generation antibodies, viruses and siRNA, from proof-of-concept laboratory studies to manufacture in preparation for clinical trials. The ultimate aim is to establish a centre of excellence for challenging drug delivery applications across a broad range of biological barriers and disease indications beyond cancer.


Contact: EPSRC Press Office
Engineering and Physical Sciences Research Council

Related medicine news :

1. Therapy sought to reduce major risk from minor bleeding that can follow stroke
2. Major lung resection safer than ever, especially at the busiest hospitals
3. Genetic alterations in shared biological pathways as major risk factor for ASD
4. Gen X obesity a major problem for healthcare, workforce
5. Surgery after major stroke also improves survival odds in elderly patients
6. A majority prefers letting computers decide
7. Major third-hand smoke compound causes DNA damage -- and potentially cancer
8. Patient requests for specific drugs have major impact on prescribing, reports study in Medical Care
9. Major League Baseball players win more games following Tommy John surgery
10. NYU researchers find majority of Latinas are unaware of their risk of diabetes
11. International study shows majority of children unaware of cigarette warning labels
Post Your Comments:
(Date:12/1/2015)... N.C. (PRWEB) , ... December 01, 2015 , ... The ... to drive awareness and funds for Multiple System Atrophy (MSA) research, timed today to ... Atrophy takes many things from patients including their ability to work and be productive, ...
(Date:12/1/2015)... ... December 01, 2015 , ... The North American Meat Institute ... meat and poultry play in a healthy, balanced diet. , includes a ... can check their “meat IQ,” a section offering straight talk on controversies, information ...
(Date:12/1/2015)... , ... December 01, 2015 , ... World Patent ... Multi Jar, a container patent that allows for easier packing and organizing of items ... is worth $90 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... area in rural West Tennessee to receive Gigabit Internet through a partnership this ... of America’s largest cities, Henderson is an attractive destination for entrepreneurs who want ...
(Date:12/1/2015)... ... ... ClinicoEconomics and Outcomes Research has published the ... ”. , As corresponding author Dr Ankita Modi says “Pre-existing gastrointestinal events may ... a large US managed care database, women aged 55 years or older with ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , December 1, 2015 Russia ... III clinical trials. 70% of new drugs registered in Europe ... in Russia . --> Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a ...
(Date:12/1/2015)... New York , December 1, 2015 ... Contraceptive Pills, Contraceptive Injectables, Topical Contraceptives, Male ... Implants, Contraceptive Vaginal Rings, Contraceptive Diaphragms, Contraceptive ... Industry Analysis, Size, Share, Growth, Trends and ... released by Transparency Market Research (TMR).The report ...
(Date:12/1/2015)... 2015  InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical ... for cardiovascular conditions via the inhalation route, today announced ... Australia . InCarda is planning to undertake ... in the first half of 2016. The ... in Adelaide and Melbourne.  In ...
Breaking Medicine Technology: